RMR6 Antibody

What is the CCR6 receptor and why is it an important research target?

CCR6 (CC chemokine receptor 6) is a G-protein-coupled receptor (GPCR) family member that is expressed on multiple immune cell populations, including B lymphocytes, effector and memory T cells, regulatory T cells, and immature dendritic cells. The interaction between CCR6 and its ligand CCL20 (CC motif chemokine ligand 20) plays significant roles in the pathogenesis of various diseases, including cancer, psoriasis, and autoimmune disorders. This widespread involvement makes CCR6 an attractive target for both therapeutic development and diagnostic applications .

How are epitopes of anti-CCR6 antibodies identified and characterized?

The epitope identification of antibodies like C6Mab-13 involves multiple complementary techniques:

• Alanine-substituted peptide scanning: This method systematically replaces each amino acid in the target sequence with alanine to identify critical binding residues. For C6Mab-13, researchers synthesized 20 different alanine-substituted mCCR6 peptides covering positions Met1 to Ser20 and tested binding via ELISA, revealing Asp11 as a critical epitope .

• Surface Plasmon Resonance (SPR): This technique measures binding affinity between antibodies and peptides, providing quantitative data on association rates (ka), dissociation rates (kd), and dissociation constants (KD). SPR analysis of C6Mab-13 identified both Gly9 and Asp11 as critical amino acids in the epitope, with additional contributions from Phe8, Thr10, Tyr13, and Asp14 .

• Flow cytometry: Complementary to in vitro binding assays, flow cytometry with cells expressing the target receptor confirms antibody specificity and provides binding affinity data in a cellular context .

What experimental differences can lead to discrepant results between epitope mapping methods?

Several factors can cause different epitope mapping methods to yield somewhat different results, as observed with C6Mab-13 where ELISA identified only Asp11 as critical while SPR identified both Gly9 and Asp11. Key factors include:

• Immobilization differences: In ELISA, synthesized peptides are immobilized on immunoplates, while in SPR, the antibody may be immobilized on a sensor chip, which can affect binding dynamics .

• Reaction kinetics: The reaction times between antigen and antibody differ significantly between methods .

• Detection system: ELISA requires secondary antibodies for detection while SPR directly measures binding events, introducing additional variables .

• Conformational effects: Peptides may adopt different conformations depending on the experimental setup, affecting epitope accessibility .

To resolve such discrepancies, researchers often employ cell-based alanine scanning or double alanine scanning for more detailed epitope analysis in relevant biological contexts .

How can binding affinity data from SPR analysis guide antibody application development?

Surface Plasmon Resonance analysis provides crucial kinetic parameters that inform antibody applications:

This data reveals that:

• Critical binding residues: Mutations that prevent KD calculation (G9A, D11A) identify essential epitope residues .

• Contributing residues: Mutations that significantly increase KD (F8A, T10A, Y13A, D14A) identify residues that contribute to binding without being absolutely essential .

• Binding mechanism insights: By analyzing association and dissociation rates separately, researchers can determine whether affinity changes are due to slower association or faster dissociation, informing antibody engineering strategies .

• Functional predictions: Recent research suggests that lower rather than higher affinity antibodies may sometimes induce greater receptor clustering and signaling. Understanding precise binding kinetics helps predict functional effects beyond simple blocking .

What factors determine whether an antibody will have neutralizing activity between a receptor and its ligand?

The ability of an antibody to neutralize receptor-ligand interactions depends on several factors:

• Epitope location: For CCR6, the binding sites for C6Mab-13 (Gly9 and Asp11) are located outside the known CCL20 binding regions (which include extracellular domains and N-terminal residues from Tyr27 to Leu38). This suggests C6Mab-13 might not directly compete with CCL20 .

• Allosteric effects: Even when not binding directly to the ligand-binding site, antibodies can induce conformational changes that allosterically affect ligand binding. This possibility exists for C6Mab-13 and requires functional studies to confirm .

• Receptor clustering: Antibodies may induce receptor clustering, potentially enhancing or inhibiting signaling independent of direct ligand competition. This is particularly relevant since recent research has shown that lower-affinity antibodies can sometimes provoke elevated activity through receptor clustering .

• Signaling pathways: Understanding the specific signaling pathways activated by CCR6 is necessary to interpret antibody effects, as blocking might affect some pathways while sparing others .

To definitively determine neutralizing activity, researchers must conduct functional assays measuring ligand-induced signaling in the presence and absence of the antibody .

How can anti-CCR6 antibodies be utilized in cancer immunotherapy research models?

Anti-CCR6 antibodies offer several potential applications in cancer immunotherapy research:

• Targeting immunosuppressive cells: CCL20 secreted by tumors attracts CCR6-expressing regulatory T cells (Tregs), which promote tumor progression and correlate with poor prognosis. Anti-CCR6 antibodies with high binding affinity, like C6Mab-13 (KD: 2.8 × 10⁻⁹ M), can be used to deplete these immunosuppressive Tregs in mouse models to evaluate antitumor effects .

• CAR-T cell development: Novel cancer treatment strategies using CCR6-expressing chimeric antigen receptor T (CAR-T) cells have been designed. Anti-CCR6 antibodies are valuable tools for characterizing these engineered cells and evaluating their specificity .

• Tumor microenvironment assessment: Anti-CCR6 antibodies can help characterize the immune cell infiltrate in tumor tissues, particularly in immunohistochemistry applications similar to those used with other immune markers like CD206 (MMR) .

• Combination therapy studies: When researching combination immunotherapies, monitoring changes in CCR6-expressing cell populations is important for understanding treatment mechanisms. High-specificity antibodies enable precise quantification of these populations by flow cytometry .

How does antibody administration timing impact experimental outcomes in immune response studies?

The timing of antibody administration critically affects experimental outcomes, as demonstrated with anti-IL-6 receptor antibody (MR16-1) studies:

These findings demonstrate that researchers must carefully consider administration timing relative to immunization or challenge when designing experiments with antibodies targeting immune receptors or cytokines .

What controls should be included when evaluating antibody specificity in epitope mapping studies?

When conducting epitope mapping studies, several critical controls should be included:

What methodological approaches can resolve contradictions between in vitro binding data and functional effects?

When researchers encounter discrepancies between binding data and functional outcomes, several approaches can help resolve these contradictions:

• Cell-based assays: While peptide-based binding studies provide valuable information about direct epitope interactions, cell-based assays evaluate antibody binding in a more physiologically relevant context with properly folded receptors. This is particularly important for multi-domain receptors like CCR6 .

• Signaling pathway analysis: Measuring multiple downstream signaling events can reveal whether antibody binding affects some pathways but not others. For CCR6, this might include calcium flux, ERK phosphorylation, and chemotaxis assays .

• Receptor clustering analysis: As noted in recent research, some antibodies can induce receptor clustering that may enhance rather than block signaling. Techniques like confocal microscopy can visualize receptor distribution before and after antibody binding .

• In vivo models: Testing antibody effects in appropriate animal models provides the most comprehensive assessment of functional outcomes. For example, C6Mab-13's potential for depleting CCR6+ Tregs in tumor models would provide functional validation beyond binding data .

• Competitive binding assays: To determine whether antibody binding affects ligand interaction, competitive binding assays with labeled natural ligands (e.g., CCL20 for CCR6) can directly measure displacement or enhancement effects .

How might anti-CCR6 antibodies be utilized in combination with other immunomodulatory approaches?

Anti-CCR6 antibodies could synergize with other immunomodulatory strategies in several ways:

• Checkpoint inhibitor combination: By depleting CCR6+ regulatory T cells using anti-CCR6 antibodies like C6Mab-13, researchers could potentially enhance the efficacy of checkpoint inhibitors like anti-PD-1/PD-L1 by reducing immunosuppression in the tumor microenvironment .

• CAR-T cell therapy enhancement: CCR6-expressing CAR-T cells have been designed for cancer treatment. Anti-CCR6 antibodies could help characterize these cells and potentially enhance their function or tracking in experimental models .

• Cytokine modulation: The observation that anti-IL-6R antibody (MR16-1) treatment increased serum IL-6 levels while suppressing immune responses provides insight into cytokine feedback mechanisms. This suggests complex interactions that should be considered when combining anti-CCR6 antibodies with cytokine-modulating approaches .

• Myeloid cell targeting: Given that macrophage markers like CD206 (MMR) are often studied alongside T cell markers in tumor contexts, combining anti-CCR6 and anti-CD206 analyses could provide comprehensive immune profiling of the tumor microenvironment .

What are the specific considerations for using anti-CCR6 antibodies in flow cytometry and immunohistochemistry?

When using anti-CCR6 antibodies for immunological techniques, researchers should consider:

• Flow cytometry optimization:

  • Cell preparation: CCR6 expression may be sensitive to enzymatic digestion methods used in sample preparation; mechanical dissociation may better preserve epitopes

  • Staining buffers: Optimizing buffers with protein blockers is essential to minimize non-specific binding

  • Gating strategy: Due to variable expression levels on different immune cell populations, proper gating controls are critical

• Immunohistochemistry applications:

  • Fixation methods: Formalin fixation may mask certain epitopes; epitope retrieval methods should be optimized

  • Signal amplification: For tissues with lower expression levels, signal amplification systems may be needed

  • Co-staining approaches: Simultaneous detection of CCR6 with other markers like CD3, CD4, or FOXP3 requires careful antibody panel design to avoid spectral overlap issues

  • Semi-quantitative analysis: Using scoring systems similar to those employed for markers like CD206 (e.g., 0=negative, 1=1-25% positivity, 2=26-50% positivity, 3=>50% positivity) enables standardized evaluation

How do variations in antibody affinity affect experimental reproducibility across different research applications?

Variations in antibody affinity can significantly impact experimental reproducibility in several ways: